Aikido Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aikido Pharma Inc (DOMH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Aikido Pharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 133M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-49.7% annualized vs trailing 12 months).
- Scale: Aikido Pharma Inc ranks #80 of 90 companies by market capitalization in the Investment Services industry, holding 0.0% of industry market cap.
- Peer revenue share: Aikido Pharma Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Peer differentiation: Revenue per employee of $3.71M compares with $0.00M for the peer group (2,559.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DOMH Sales vs. its Competitors, Q2 2026
Aikido Pharma Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Investment Services industry grew revenue -3.0% year over year, combined, vs -56.9% for Aikido Pharma Inc. Aikido Pharma Inc's share of combined industry revenue moved from 0.01% to 0.01%, a loss of 0.01 percentage points.
Aikido Pharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aikido Pharma Inc | No | Yes | Yes | Yes |
| Competitors combined (1) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 83.30 % (5 of 6) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DOMH Stock Performance relative to its Competitors
DOMH Stock Performance relative to Similar-Size Competitors
DOMH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Bank Bradesco | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Aikido Pharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Aikido Pharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Aikido Pharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Aikido Pharma Inc |
31.86 | 133.49 |
 Bank Bradesco |
13,455.15 | 118.96 |
| SUBTOTAL | 13,487.01 | 252.45 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aikido Pharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aikido Pharma Inc's Competitors Named by the Company
Competitive relationships identified from Aikido Pharma Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bank Bradesco | Company report | 85% |
| Partners Bancorp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Aikido Pharma Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Aikido Pharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aikido Pharma Inc | 32 | 3,708,139 | -1,884,167 |
| Bank Bradesco | 13,455 | 1,449 | 52,215 |
| PEERS TOTAL | 13,455 | 1,449 | 52,215 |
Aikido Pharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 88 companies in Aikido Pharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Aikido Pharma Inc ranks #80 of 88 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 580, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Morgan Stanley | 284,679 | 12.54 % |
| 2 | The Goldman Sachs Group Inc | 263,989 | 11.62 % |
| 3 | Blackrock Inc | 194,098 | 8.55 % |
| 4 | Schwab Charles Corp | 159,101 | 7.01 % |
| 5 | Futu Holdings Ltd | 1,234 | 5.2% |
| 6 | Cme Group Inc | 1,234 | 5.2% |
| 7 | Intercontinental Exchange Inc | 1,234 | 5.2% |
| 8 | Blackstone Inc | 1,234 | 5.2% |
| 9 | Kkr and co inc | 1,234 | 5.2% |
| 10 | Brookfield Asset Management Ltd | 1,234 | 5.2% |
| 80 | Aikido Pharma Inc | 32 | 0.00 % |
Market cap and industry share for the rest of Aikido Pharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Aikido Pharma Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 75 | Waton Financial Limited | 83 | -60.96 % |
| 76 | Hennessy Advisors Inc | 82 | 6.30 % |
| 77 | Siebert Financial Corp | 73 | -38.11 % |
| 78 | Cohen and Co Inc | 64 | 3.63 % |
| 79 | Mount Logan Capital Inc | 1,234 | 12.3% |
| 80 | Aikido Pharma Inc | 32 | -70.29 % |
| 81 | U S Global Investors Inc | 1,234 | 12.3% |
| 82 | Plutus Financial Group Limited | 1,234 | 12.3% |
| 83 | Ebang International Holdings Inc | 1,234 | 12.3% |
| 84 | Wright Investors Service Holdings Inc | 1,234 | 12.3% |
| 85 | Morgan Group Holding Co | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Aikido Pharma Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Aikido Pharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Investment Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (142 companies). See the full Investment Services industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 20.94 % (avg) | -20.9 pp |
| Operating Margin | -31.60 % | industry median | -66.6 pp |
| EBITDA Margin | 72.71 % | 22.57 % (avg) | +50.1 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 3.63 % (avg) | -3.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Aikido Pharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Investment Services industry average (142 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Investment Services industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.3x | - |
| EV / EBITDA | 0.5x | 12.5x | -12.0x |
| P/B | 0.9x | 3.5x | -2.7x |
| Return on Equity | -81.44 % | industry aggregate | -97.29 % |
| Return on Invested Capital | -22.43 % | 6.42 % (avg) | -28.85 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Aikido Pharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | 500.00 % |
| Operating Margin | - | - | - | - | - | - | -63.52 % | -40.26 % |
| Return on Invested Capital | -37.50 % | -27.50 % | -11.76 % | -4.58 % | -8.33 % | -17.54 % | -13.24 % | -23.47 % |
| P/E | 367.2x | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Aikido Pharma Inc's Strategic Group Map
Aikido Pharma Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Aikido Pharma Inc's trailing-12-month revenue growth of 135.2% and operating margin of -31.6% compares with an average of 98.0% growth and 9.9% margin across its 8 closest peers by combined growth, margin and ROIC -- Aikido Pharma Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Aikido Pharma Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Aikido Pharma Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Aikido Pharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 580 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 3.63 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Aikido Pharma Inc's dedicated Suppliers and Customers pages, not here.
Aikido Pharma Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Aikido Pharma Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Aikido Pharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 66.6 points below the industry median.
- Return on equity 97.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-49.7% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Aikido Pharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aikido Pharma Inc | 2.76 | 11.09 | - |
| Bank Bradesco | 90.31 | 6.18 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aikido Pharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aikido Pharma Inc | Q2 2026 | -56.9 % | - |
| Bank Bradesco | Q4 2025 | -71.8 % | +31.1 % |
| PEERS TOTAL | -70.5 % | +30.2 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aikido Pharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aikido Pharma Inc | Q2 2026 | - | - |
| Bank Bradesco | Q4 2025 | -9.8 % | +110.2 % |
Aikido Pharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aikido Pharma Inc | - | - | - |
| Bank Bradesco | 1.01% | 0.97% | 13.12% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aikido Pharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aikido Pharma Inc | - | 0.24 |
| Bank Bradesco | 0.57 | 113.11 |
| PEERS AVERAGE | 3.20 | 53.42 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.